![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical firm targeted on growing and commercializing progressive antibody-based therapeutics for the therapy of most cancers, right now introduced that the Company’s administration will take part in the next investor conferences in November 2022.
- BMO Biopharma Spotlight Series | Oncology Day (Virtual). Members of MacroGenics’ senior administration staff will take part in a fireplace chat on Wednesday, November 9 at 2:30 pm ET. A replay hyperlink will likely be supplied after the convention. MacroGenics’ administration may even take part in one-on-one conferences.
- Stifel 2022 Healthcare Conference (New York). MacroGenics’ President & CEO, Scott Koenig, M.D., Ph.D., will take part in a fireplace chat on Tuesday, November 15 at 10:55 am ET. MacroGenics’ administration may even take part in one-on-one conferences.
- Evercore ISI 5th Annual HEALTHCONx Conference (Virtual). MacroGenics’ President & CEO, Scott Koenig, M.D., Ph.D., will take part in a fireplace chat on Wednesday, November 30 at 8:50 am ET. MacroGenics’ administration may even take part in one-on-one conferences.
Webcasts of the above could also be accessed underneath “Events & Presentations” in the Investor Relations part of MacroGenics’ web site at http://ir.macrogenics.com/events.cfm. The Company maintains archived replays of webcasts on its web site for 30 days after the convention.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical firm targeted on growing and commercializing progressive antibody-based therapeutics for the therapy of most cancers. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based expertise platforms, which have applicability throughout broad therapeutic domains. The mixture of MacroGenics’ expertise platforms and protein engineering experience has allowed the Company to generate promising product candidates and enter into a number of strategic collaborations with international pharmaceutical and biotechnology corporations. For extra info, please see the Company’s web site at www.macrogenics.com. MacroGenics and the MacroGenics brand are emblems or registered emblems of MacroGenics, Inc.
###
